van den Berg HM - Search Results

1

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A.

van den Berg HM, Fischer K, Carcao M, Chambost H, Kenet G, Kurnik K, Königs C, Male C, Santagostino E, Ljung R; PedNet Study Group. van den Berg HM, et al. Blood. 2019 Jul 18;134(3):317-320. doi: 10.1182/blood.2019000658. Epub 2019 Jun 11. Blood. 2019. PMID: 31186271 Free article. No abstract available.

2

Low-dose immune tolerance induction in hemophilia A patients with inhibitors.

Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Mauser-Bunschoten EP, et al. Among authors: van den berg hm. Blood. 1995 Aug 1;86(3):983-8. Blood. 1995. PMID: 7620189 Free article.

3

A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group.

Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, Smit C, Strengers PF, Briët E. Rosendaal FR, et al. Among authors: van den berg hm, van der meer j. Blood. 1993 Apr 15;81(8):2180-6. Blood. 1993. PMID: 8471777 Free article.

4

Kinetics of factor VIII-von Willebrand factor association.

Vlot AJ, Koppelman SJ, Meijers JC, Dama C, van den Berg HM, Bouma BN, Sixma JJ, Willems GM. Vlot AJ, et al. Among authors: van den berg hm. Blood. 1996 Mar 1;87(5):1809-16. Blood. 1996. PMID: 8634427 Free article.

5

The use of the Port-A-Cath in children with haemophilia--a review.

Van Den Berg HM, Fischer K, Roosendaal G, Mauser-Bunschoten EP. Van Den Berg HM, et al. Haemophilia. 1998 Jul;4(4):418-20. doi: 10.1046/j.1365-2516.1998.440418.x. Haemophilia. 1998. PMID: 9873764 Review.

6

Endogenous clotting factor activity and long-term outcome in patients with moderate haemophilia.

Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Beek FJ, de Kleijn P, Grobbee DE, van den Berg HM. Fischer K, et al. Among authors: van den berg hm, van der bom jg. Thromb Haemost. 2000 Dec;84(6):977-80. Thromb Haemost. 2000. PMID: 11154144

7

Long-term outcome of individualized prophylactic treatment of children with severe haemophilia.

van den Berg HM, Fischer K, Mauser-Bunschoten EP, Beek FJ, Roosendaal G, van der Bom JG, Nieuwenhuis HK. van den Berg HM, et al. Among authors: van der bom jg. Br J Haematol. 2001 Mar;112(3):561-5. doi: 10.1046/j.1365-2141.2001.02580.x. Br J Haematol. 2001. PMID: 11260054 Free article.

8

Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.

Mauser-Bunschoten EP, van der Bom JG, Bongers M, Twijnstra M, Roosendaal G, Fischer K, van den Berg HM. Mauser-Bunschoten EP, et al. Among authors: van den berg hm, van der bom jg. Haemophilia. 2001 Jul;7(4):364-8. doi: 10.1046/j.1365-2516.2001.00513.x. Haemophilia. 2001. PMID: 11442640

9

Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy.

Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, Grobbee DE, van den Berg HM. Fischer K, et al. Among authors: van den berg hm, van der bom jg. Haemophilia. 2001 Sep;7(5):446-52. doi: 10.1046/j.1365-2516.2001.00545.x. Haemophilia. 2001. PMID: 11554930

10

Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome.

Fischer K, Van Der Bom JG, Prejs R, Mauser-Bunschoten EP, Roosendaal G, Grobbee DE, Van Den Berg HM. Fischer K, et al. Among authors: van den berg hm, van der bom jg. Haemophilia. 2001 Nov;7(6):544-50. doi: 10.1046/j.1365-2516.2001.00560.x. Haemophilia. 2001. PMID: 11851751

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

255 results

Search Page

Filters